CAR T-cell therapies are in clinical trials and have not yet received regulatory approval for the treatment of any disease or condition.
Customers are responsible for validating the use of the Elutra system to separate cells for their intended therapy.
Customers are responsible for validating the use of the Quantum system to expand cells for their intended therapy.
Click the link below to view the "CAR-T Cell Therapies From the Transfusion Medicine Perspective" Article.
Click the link below to view the "Elutriated lymphocytes for manufacturing chimeric antigen receptor T-cells" Article.
This white paper demonstrates the expansion of T-cells in the Quantum® Cell Expansion System.
Results from a single stimulation event showed that the Quantum system produced 90- to 500-fold expansion of T-cells starting from an apheresis blood collection in as little as 13 days.
The enhanced manufacturing process control of an automated and functionally closed system can help reduce the labor and the number of open events involved in T-cell expansion, which may result in more efficient production and scale-out of cellular production.
Click the link below to sign up and read this article.
Products available in select markets.